Clinical Trials
49 trialsNCT05923060 2026-02-20
Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT06027619 2025-10-23
Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT06319794 2025-07-18
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
TORQUR
Phase 2 Completed
NCT01998984 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 2 Completed
NCT02305888 2025-03-10
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
LEO Pharma
Phase 2 Completed
NCT02844777 2023-01-12
Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis
Vidac Pharma
Phase 2 Completed
NCT03006185 2022-09-28
Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin
Bispebjerg Hospital
Phase 2 Completed
NCT03538951 2022-08-23
Phase2b
Vidac Pharma
Phase 2 Completed
NCT04140292 2022-06-24
Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00189267 2022-02-07
A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
Viatris Inc.
Phase 2 Completed
NCT02838628 2021-04-14
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
Almirall, S.A.
Phase 2 Completed
NCT03914417 2021-01-20
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02404389 2021-01-05
Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients
Novartis
Phase 2 Completed
NCT03122457 2020-09-04
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02654717 2020-03-17
Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp
Promius Pharma, LLC
Phase 2 Completed
NCT03606122 2019-08-28
5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities
photonamic GmbH & Co. KG
Phase 2 Completed
NCT03083470 2019-05-15
Study of SOR007 Ointment for Actinic Keratosis
DFB Soria, LLC
Phase 2 Completed
NCT03210740 2019-04-30
Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis
AmDerma
Phase 2 Completed
NCT01516515 2018-12-05
Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis
G&E Herbal Biotechnology Co., LTD
Phase 2 Completed
NCT00021294 2018-09-11
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
University of Arizona
Phase 2 Completed
NCT02239679 2018-08-24
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02632110 2018-01-18
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02628236 2017-09-18
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02281136 2017-01-13
Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT01475955 2016-10-28
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02799030 2016-07-19
A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis
Biofrontera Bioscience GmbH
Phase 2 Completed
NCT02126670 2016-02-22
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Promius Pharma, LLC
Phase 2 Completed
NCT00375739 2016-01-28
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
Peplin
Phase 2 Completed
NCT01583816 2015-12-15
Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions
Spirig Pharma Ltd.
Phase 2 Completed
NCT00089180 2015-12-04
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
National Cancer Institute (NCI)
Phase 2 Completed
NCT00427050 2015-09-14
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
Peplin
Phase 2 Completed
NCT00786994 2015-09-14
The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
Amryt Pharma
Phase 2 Completed
NCT00991861 2015-05-29
Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis
Almirall, S.A.
Phase 2 Completed
NCT01358851 2015-05-29
LAS41005 in Hyperkeratotic Actinic Keratosis
Almirall, S.A.
Phase 2 Completed
NCT00700063 2015-04-14
A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
Peplin
Phase 2 Completed
NCT00544297 2015-04-02
A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand
Peplin
Phase 2 Completed
NCT00608634 2015-04-01
Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses
University of Arizona
Phase 2 Completed
NCT00107965 2015-03-25
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
Peplin
Phase 2 Completed
NCT00239135 2015-03-25
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
Peplin
Phase 2 Completed
NCT01921907 2015-03-10
Evaluation of a Topical Treatment for Actinic Keratosis
Assuta Hospital Systems
Phase 2 Completed
NCT00852137 2015-03-06
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
Peplin
Phase 2 Completed
NCT02278861 2014-10-30
ARISOAK
Universidade Federal de Goias
Phase 2 Completed
NCT02085395 2014-03-14
AK
G&E Herbal Biotechnology Co., LTD
Phase 2 Completed
NCT00002975 2013-10-10
Photodynamic Therapy in Treating Patients With Skin Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT01611480 2013-06-26
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
Moberg Pharma AB
Phase 2 Completed
NCT01458587 2013-03-14
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT01214564 2011-01-25
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
Peplin
Phase 2 Completed
NCT00335179 2010-07-23
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
Graceway Pharmaceuticals, LLC
Phase 2 Completed
NCT00269074 2009-03-20
Effect of IDEA-070 on Pain and Inflammation Induced by PDT
IDEA AG
Phase 2 Completed